Literature DB >> 31672769

A Solution to the Dilution: The Role for Biomarkers in Advanced Ovarian Cancer.

Katelyn F Handley1, Anil K Sood2.   

Abstract

Reliable approaches to predict residual disease prior to primary debulking surgery have been sought to further personalize surgical approaches. Reliance on molecular biomarkers alone in a complex clinical environment is challenging and algorithms that incorporate both molecular and clinical features may need to be considered.See related article by Heitz et al., p. 213. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31672769      PMCID： PMC6942626          DOI： 10.1158/1078-0432.CCR-19-3072

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  7 in total

1.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

Authors:  Sean Kehoe; Jane Hook; Matthew Nankivell; Gordon C Jayson; Henry Kitchener; Tito Lopes; David Luesley; Timothy Perren; Selina Bannoo; Monica Mascarenhas; Stephen Dobbs; Sharadah Essapen; Jeremy Twigg; Jonathan Herod; Glenn McCluggage; Mahesh Parmar; Ann-Marie Swart
Journal:  Lancet       Date:  2015-05-19       Impact factor: 79.321

2.  Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.

Authors:  Susan L Tucker; Kshipra Gharpure; Shelley M Herbrich; Anna K Unruh; Alpa M Nick; Erin K Crane; Robert L Coleman; Jamie Guenthoer; Heather J Dalton; Sherry Y Wu; Rajesha Rupaimoole; Gabriel Lopez-Berestein; Bulent Ozpolat; Cristina Ivan; Wei Hu; Keith A Baggerly; Anil K Sood
Journal:  Clin Cancer Res       Date:  2014-04-22       Impact factor: 12.531

3.  Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.

Authors:  Nicole D Fleming; Alpa M Nick; Robert L Coleman; Shannon N Westin; Pedro T Ramirez; Pamela T Soliman; Bryan Fellman; Larissa A Meyer; Kathleen M Schmeler; Karen H Lu; Anil K Sood
Journal:  Obstet Gynecol       Date:  2018-09       Impact factor: 7.661

4.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Authors:  Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

5.  Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation.

Authors:  Zhenqiu Liu; Jessica A Beach; Hasmik Agadjanian; Dongyu Jia; Paul-Joseph Aspuria; Beth Y Karlan; Sandra Orsulic
Journal:  Gynecol Oncol       Date:  2015-09-06       Impact factor: 5.482

6.  Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples.

Authors:  Markus Riester; Wei Wei; Levi Waldron; Aedin C Culhane; Lorenzo Trippa; Esther Oliva; Sung-Hoon Kim; Franziska Michor; Curtis Huttenhower; Giovanni Parmigiani; Michael J Birrer
Journal:  J Natl Cancer Inst       Date:  2014-04-03       Impact factor: 13.506

7.  Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer.

Authors:  Florian Heitz; Stefan Kommoss; Roshan Tourani; Anthony Grandelis; Locke Uppendahl; Constantin Aliferis; Alexander Burges; Chen Wang; Ulrich Canzler; Jinhua Wang; Antje Belau; Sonia Prader; Lars Hanker; Sisi Ma; Beyhan Ataseven; Felix Hilpert; Stephanie Schneider; Jalid Sehouli; Rainer Kimmig; Christian Kurzeder; Barbara Schmalfeldt; Elena I Braicu; Philipp Harter; Sean C Dowdy; Boris J Winterhoff; Jacobus Pfisterer; Andreas du Bois
Journal:  Clin Cancer Res       Date:  2019-09-16       Impact factor: 12.531
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.